Sophia Taylor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sophia Taylor has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Louisa Degenhardt
National Drug and Alcohol Research Centre University of New South Wales Sydney New South Wales Australia
5 shared publications - Michelle Lynch
National Drug and Alcohol Research Centre (NDARC), University of New South Wales Sydney (UNSW Sydney), Sydney, Australia
5 shared publications - Thomas Santo
National Drug and Alcohol Research Centre UNSW Sydney Sydney Australia
5 shared publications - Jason Grebely
The Kirby Institute University of New South Wales Sydney New South Wales Australia
3 shared publications Michael Farrell
National Drug and Alcohol Research Centre UNSW Sydney Sydney Australia
3 shared publicationsAleksa Kamenjaš
National Drug and Alcohol Research Centre (NDARC), University of New South Wales Sydney (UNSW Sydney), Sydney, Australia
2 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 56, e324
Prevalence of mental health outcomes among trans and gender diverse adults: a global systematic review and meta-analysis
Existing reviews of mental health outcomes among trans and gender diverse (trans)people have been limited by incomplete coverage, restricted or selected samples, afocus on youth populations, and insufficient exploration of heterogeneity. We aimed togenerate pooled prevalence estimates, and examine variation in mental disorders,suicidality, and non-suicidal selfinjury (NSSI) among trans adults globally. Weconducted a systematic review and meta-analysis of studies reporting current orlifetime prevalence of mental disorders, assessed using symptom screeninginstruments with validated general-population thresholds or clinical diagnoses,alongside self-reported suicidality and NSSI. MEDLINE, Embase, and PsycINFO weresearched from January 1, 1990-April 7, 2026. Restricted or highly selectedsubpopulations were excluded, except for gender-affirming clinic samples. Estimateswere calculated overall and by gender identity. Subgroup/meta-regression analysesexamined variation by study and sociodemographic characteristics. We identified 207studies with 134,071 trans participants across 52 countries. Pooled prevalenceestimates, combining symptoms exceeding screening thresholds and clinicallydiagnosed disorders, were 40.1% (95% CI 35.6-44.8) for depression, 29.8% (20.3-40.2) for anxiety, and 23.6% (14.9-33.5) for post-traumatic stress disorder. Past-12-month prevalence was 43.1% (38.9-47.3) for suicidal ideation, 9.3%(7.7-11.0) forsuicide attempts, and 26.1% (20.4-32.2) for NSSI. Limited data suggested higherprevalences among non-binary participants. Prevalence estimates varied significantlyby assessment method, recruitment setting, and geographic region. Trans peopleexperience a substantial burden of mental disorders, suicidality, and NSSI. Elevatedprevalence relative to general population comparator estimates indicates a need for affirming, accessible mental healthcare and improved approaches to assessing andinterpreting mental health outcomes in trans populations.
- 8 October 2026
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 56, e324
Open AccessPrevalence of mental health outcomes among trans and gender diverse adults: a global systematic review and meta-analysis
Existing reviews of mental health outcomes among trans and gender diverse (trans)people have been limited by incomplete coverage, restricted or selected samples, afocus on youth populations, and insufficient exploration of heterogeneity. We aimed togenerate pooled prevalence estimates, and examine variation in mental disorders,suicidality, and non-suicidal selfinjury (NSSI) among trans adults globally. Weconducted a systematic review and meta-analysis of studies reporting current orlifetime prevalence of mental disorders, assessed using symptom screeninginstruments with validated general-population thresholds or clinical diagnoses,alongside self-reported suicidality and NSSI. MEDLINE, Embase, and PsycINFO weresearched from January 1, 1990-April 7, 2026. Restricted or highly selectedsubpopulations were excluded, except for gender-affirming clinic samples. Estimateswere calculated overall and by gender identity. Subgroup/meta-regression analysesexamined variation by study and sociodemographic characteristics. We identified 207studies with 134,071 trans participants across 52 countries. Pooled prevalenceestimates, combining symptoms exceeding screening thresholds and clinicallydiagnosed disorders, were 40.1% (95% CI 35.6-44.8) for depression, 29.8% (20.3-40.2) for anxiety, and 23.6% (14.9-33.5) for post-traumatic stress disorder. Past-12-month prevalence was 43.1% (38.9-47.3) for suicidal ideation, 9.3%(7.7-11.0) forsuicide attempts, and 26.1% (20.4-32.2) for NSSI. Limited data suggested higherprevalences among non-binary participants. Prevalence estimates varied significantlyby assessment method, recruitment setting, and geographic region. Trans peopleexperience a substantial burden of mental disorders, suicidality, and NSSI. Elevatedprevalence relative to general population comparator estimates indicates a need for affirming, accessible mental healthcare and improved approaches to assessing andinterpreting mental health outcomes in trans populations.
- Open Access
- 18 March 2026
- Published by Wiley in Drug and Alcohol Review
- Vol. 45 (3) , e70132
Factors Associated With Opioid Agonist Treatment Engagement and Harm Reduction Service Use: Findings From the New South Wales Opioid Dependence Survey
Introduction: Opioid agonist treatment (OAT) is one of the most effective treatments for opioid dependence, but there can be barriers to accessing treatment. This study examined characteristics associated with OAT engagement—never, previous or current—among people with opioid dependence in NSW, Australia, following recent reforms to OAT access. Methods: Between October 2023 and March 2024, people with opioid dependence were recruited from services and community settings across NSW. Participants completed structured interviews on socio‐demographics, mental health disorders, substance use and use of prevention and treatment services. Logistic regression was used to examine associations between participant characteristics and engagement with OAT. Results: Of 403 participants (mean age 44; 65% male), 77% were currently receiving OAT (60% methadone, 11% sublingual buprenorphine and 27% long‐acting injectable buprenorphine), 13% previously and 9% never. Differences between OAT status groups included those currently receiving OAT reporting lower rates of homelessness and extra‐medical opioid use, and greater group therapy engagement and past‐year receipt of naloxone kits compared to those previously and never receiving OAT. Past‐month daily injecting drug use was higher among those previously and never receiving OAT; those previously receiving OAT also reported the highest rate of past‐year supervised injecting facility use and overdoses in the past 6 months. Discussion and Conclusions: Those not receiving OAT reported greater social instability, recent injecting drug use and drug‐related harm. Variation in harm reduction service use suggests tailored strategies are needed to reach those outside OAT . These findings highlight the need for integrated, diverse strategies to address dependence‐related harms.
- 18 March 2026
- Published by Wiley in Drug and Alcohol Review
- Vol. 45 (3) , e70132
Open AccessFactors Associated With Opioid Agonist Treatment Engagement and Harm Reduction Service Use: Findings From the New South Wales Opioid Dependence Survey
Introduction: Opioid agonist treatment (OAT) is one of the most effective treatments for opioid dependence, but there can be barriers to accessing treatment. This study examined characteristics associated with OAT engagement—never, previous or current—among people with opioid dependence in NSW, Australia, following recent reforms to OAT access. Methods: Between October 2023 and March 2024, people with opioid dependence were recruited from services and community settings across NSW. Participants completed structured interviews on socio‐demographics, mental health disorders, substance use and use of prevention and treatment services. Logistic regression was used to examine associations between participant characteristics and engagement with OAT. Results: Of 403 participants (mean age 44; 65% male), 77% were currently receiving OAT (60% methadone, 11% sublingual buprenorphine and 27% long‐acting injectable buprenorphine), 13% previously and 9% never. Differences between OAT status groups included those currently receiving OAT reporting lower rates of homelessness and extra‐medical opioid use, and greater group therapy engagement and past‐year receipt of naloxone kits compared to those previously and never receiving OAT. Past‐month daily injecting drug use was higher among those previously and never receiving OAT; those previously receiving OAT also reported the highest rate of past‐year supervised injecting facility use and overdoses in the past 6 months. Discussion and Conclusions: Those not receiving OAT reported greater social instability, recent injecting drug use and drug‐related harm. Variation in harm reduction service use suggests tailored strategies are needed to reach those outside OAT . These findings highlight the need for integrated, diverse strategies to address dependence‐related harms.
- Open Access
- 5 February 2026
- Published by Elsevier in International Journal of Drug Policy
- Vol. 150, 105069
Global coverage of interventions for reduction of injecting drug use-related harm, HIV, viral hepatitis and tuberculosis in prisons and other carceral settings: A systematic review
- 5 February 2026
- Published by Elsevier in International Journal of Drug Policy
- Vol. 150, 105069
Open AccessGlobal coverage of interventions for reduction of injecting drug use-related harm, HIV, viral hepatitis and tuberculosis in prisons and other carceral settings: A systematic review
- Top Cited PapersOpen Access
- 5 February 2026
- Published by Elsevier in International Journal of Drug Policy
- Vol. 150, 105062
The global epidemiology of injecting drug use, HIV, viral hepatitis and tuberculosis among people who are incarcerated: a multistage systematic review
- 5 February 2026
- Published by Elsevier in International Journal of Drug Policy
- Vol. 150, 105062
Top Cited PapersOpen AccessThe global epidemiology of injecting drug use, HIV, viral hepatitis and tuberculosis among people who are incarcerated: a multistage systematic review
- Open Access
- 25 June 2025
- Published by Wiley in Drug and Alcohol Review
- Vol. 44 (6) , 1601-1640
Global Perspectives on Kava: A Narrative Systematic Review of the Health Effects, Economic and Social Impacts and Policy Considerations
Introduction: Kava is a plant‐based drug central to many Pacific Island cultures, yet its physiological and psychological effects remain contested and poorly understood. Additionally, the broader social, economic, and policy consequences of kava trade and consumption are unclear. This paper systematically reviewed global literature on kava to clarify its role and potential impacts across these domains.Methods: We conducted a systematic search of eight databases for records published between January 1980 and December 2022. Records on kava prevalence, social and cultural use, harms, benefits, economic impacts and policy reports were included. Data were narratively synthesised, combining qualitative and quantitative data extracted using a pre‐designed template for each outcome, including a risk of bias evaluation.Results: We included 197 records across all domains. Most prevalence records used convenience samples in populations regularly consuming kava but with varying doses and periods. The harms and benefits of kava varied; its role in liver toxicity and anxiety reduction remains unclear. However, kava's social and cultural uses in recreational and traditional contexts and its economic importance in trade, distribution and sales across Pacific Islander countries were consistently reported.Discussion and Conclusions: Kava holds social and cultural significance and is an essential trading commodity for Pacific Islander countries. Additional high‐quality studies with larger samples are necessary to better inform policies and regulations around kava's usage, distribution, and its potential harms and benefits.
- 25 June 2025
- Published by Wiley in Drug and Alcohol Review
- Vol. 44 (6) , 1601-1640
Open AccessGlobal Perspectives on Kava: A Narrative Systematic Review of the Health Effects, Economic and Social Impacts and Policy Considerations
Introduction: Kava is a plant‐based drug central to many Pacific Island cultures, yet its physiological and psychological effects remain contested and poorly understood. Additionally, the broader social, economic, and policy consequences of kava trade and consumption are unclear. This paper systematically reviewed global literature on kava to clarify its role and potential impacts across these domains.Methods: We conducted a systematic search of eight databases for records published between January 1980 and December 2022. Records on kava prevalence, social and cultural use, harms, benefits, economic impacts and policy reports were included. Data were narratively synthesised, combining qualitative and quantitative data extracted using a pre‐designed template for each outcome, including a risk of bias evaluation.Results: We included 197 records across all domains. Most prevalence records used convenience samples in populations regularly consuming kava but with varying doses and periods. The harms and benefits of kava varied; its role in liver toxicity and anxiety reduction remains unclear. However, kava's social and cultural uses in recreational and traditional contexts and its economic importance in trade, distribution and sales across Pacific Islander countries were consistently reported.Discussion and Conclusions: Kava holds social and cultural significance and is an essential trading commodity for Pacific Islander countries. Additional high‐quality studies with larger samples are necessary to better inform policies and regulations around kava's usage, distribution, and its potential harms and benefits.
- Open Access
- 26 April 2024
- Published by Elsevier in International Journal of Drug Policy
- Vol. 128, 104434
Prevalence of comorbid substance use disorders among people with opioid use disorder: A systematic review & meta-analysis
- 26 April 2024
- Published by Elsevier in International Journal of Drug Policy
- Vol. 128, 104434
Open AccessPrevalence of comorbid substance use disorders among people with opioid use disorder: A systematic review & meta-analysis